CRISPR THERAPEUTICS AG— Sankey Diagram

Annual mode · period ending 2025-12-31 · SEC EDGAR

FY2025 - Q4(Oct 25 · Nov 25 · Dec 25)
Total Assets
$2.27B
↑+1.0% +$23Mvs FY2024
Total Liabilities
$343M
↑+10.8% +$33Mvs FY2024
Equity
$1.92B
↓-0.5% -$10Mvs FY2024
Cash
$348M
↑+16.5% +$49Mvs FY2024
Click a Metric or Sankey Node to View Historical Trends
Show Source Data (Audit Panel)
Reconciled values per the annual mode pipeline. Compare against SEC EDGAR filings.
Line itemFY2025FY2024
Total Assets$2.27B$2.24B
Current Assets$1.99B$1.94B
Cash$348M$298M
ST Investments$1.63B$1.61B
Receivables$0$25M
Inventory$0$0
Other Current$10M$8M
Non-Current Assets$280M$305M
PPE$116M$134M
Goodwill$0$0
Intangibles$0$0
Investments$0$0
Other Non-Current$164M$171M
Total Liab+Eq$2.27B$2.24B
Current Liab.$149M$88M
Accounts Payable$11M$15M
Short-Term Debt$0$0
Deferred Revenue$16M$4M
Other CL$122M$69M
Non-Current Liab.$194M$222M
Long-Term Debt$0$0
Other LT Liab.$194M$222M
Equity$1.92B$1.93B
Retained Earnings$1.95B$1.37B
Other Equity$0$566M

QuarterCharts · SEC EDGAR data · CRSP · Comparing FY2025 vs FY2024